# EDGAR Filing Document

**Accession Number:** 0001042418
**File Stem:** 0001641172-25-020608
**Filing Date:** 2025-7
**Character Count:** 3768
**Document Hash:** c835524f4d68a57e1efb64ddfa3b9229
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-020608.hdr.sgml**: 20260122

**ACCESSION NUMBER**: 0001641172-25-020608

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250722

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibitor Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042418
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 541641133
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609
- **BUSINESS PHONE:** (813) 766-2462

**MAIL ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HedgePath Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMONWEALTH BIOTECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970714

**Inhibitor Therapeutics, Inc.**

**3014 W. Palmira Avenue**

**Suite 302**

**Tampa, FL 33629**

***<u>VIA EDGAR</u>***

July 22, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Joshua Gorsky Chris Edwards

---

| | |
|:---|:---|
| **Re:** | **Inhibitor Therapeutics, Inc.** |
|  | **Form 10-K for the Year Ended December 31, 2024** |
|  | **Filed March 28, 2025** |
|  | **File No. 001-13467** |

---

Ladies and Gentlemen:

Inhibitor Therapeutics, Inc. (the "**Company**," "**we**," "**our**" or "**us**") hereby transmits our response to the comment letter received from the staff (the "**Staff**", "**you**" or "**your**") of the U.S. Securities and Exchange Commission (the "**Commission**"), dated July 17, 2025, regarding the Form 10-K for the fiscal year ended December 31, 2024 (the "**Form 10-K**") submitted to the Commission on.

For the Staff's convenience, we have repeated below the Staff's comment in bold and have followed each comment with the Registrants' response. In response to the Staff's comments, the Registrants are filing via Edgar a response letter.

**<u>Annual Report on Form 10-K</u>**

**<u>Item 1. Description of Business, page 3</u>**

&nbsp;&nbsp;&nbsp;&nbsp;**1.** **We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable.** 

<u>Response</u>: In response to the Staff's comment, the Company respectfully advises the Staff that it will revise the disclosure in future filings, initially in its Form 10-Q for the fiscal quarter ended June 30, 2025, to include the material terms of the agreement, including the aggregate milestone amounts to be paid, and the royalty range and term, as applicable, for the Exclusive License Agreement with Johns Hopkins University.

We thank the Staff in advance for its consideration of the foregoing. Should you have any questions, please do not hesitate to contact our legal counsel, Justin Grossman, Esq., of Ellenoff Grossman & Schole LLP, at (212) 370-1300.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| By: | */s/ James A. McNulty* |
| Name: | James A. McNulty |
| Title: | Chief Financial Officer |

---

cc: Ellenoff Grossman & Schole LLP